Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial
Background CAVE is a single arm, Phase 2 trial, that demonstrated anti-tumor activity of cetuximab rechallenge plus avelumab in patients with RAS wild type (wt) metastatic colorectal cancer (mCRC). Objective We conducted a post hoc analysis to identify potential radiomic biomarkers for patients with...
Gespeichert in:
Veröffentlicht in: | Clinical drug investigation 2024-07, Vol.44 (7), p.541-548 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
CAVE is a single arm, Phase 2 trial, that demonstrated anti-tumor activity of cetuximab rechallenge plus avelumab in patients with
RAS
wild type (wt) metastatic colorectal cancer (mCRC).
Objective
We conducted a post hoc analysis to identify potential radiomic biomarkers for patients with CRC liver metastasis (LM).
Patients and Methods
Patients with LM that could be measured by enhanced contrast phase computed tomography (CT) imaging at baseline and at first response evaluation were included. Multiple texture parameters were extracted with the LifeX Software. Delta-texture (D-TA) variations were calculated by comparing data at baseline and after treatment.
Results
Overall, 55/77 patients (71%) had LM; 39 met the inclusion criteria for the current analysis. The D-TA parameters that significantly correlated at univariate analysis with median progression-free survival (mPFS) were Entropy
Histogram
(
p
= 0.021), Homogeneity
GLCM
(
p
< 0.001) and Dissimilarity
GLCM
(
p
= 0.002). At multivariate analysis, only Homogeneity
GLCM
resulted significant for PFS (
p
= 0.001). Patients (19/39, 48.7%) with reduction of Homogeneity
GLCM
experienced better mPFS (4.6 vs 2.9 months; HR 0.45; 95% CI 0.23–0.88;
p
= 0.021) and median overall survival (mOS) (17.3 vs 6.8 months; HR 0.40, 95% CI 0.21–0.80;
p
= 0.010). A trend to better mPFS, was also observed in patients with
RAS/BRAF
wt circulating tumor DNA and reduction of Homogeneity
GLCM
. Overall survival was significantly better in this subgroup of patients with low Homogeneity
GLCM
: mOS was 17.8 (95% CI 15.5–20.2) versus 6.8 months (95% CI 3.6–10.0) (HR 0.34, 95% CI 0.14–0.81;
p
= 0.016).
Conclusion
Reduction in the D-TA parameter Homogeneity
GLCM
by radiomic analysis correlates with improved outcomes in patients with LM receiving cetuximab rechallenge plus avelumab therapy. Larger prospective studies are needed to validate and confirm these findings. |
---|---|
ISSN: | 1173-2563 1179-1918 1179-1918 |
DOI: | 10.1007/s40261-024-01372-0 |